259 related articles for article (PubMed ID: 24214898)
1. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.
Raykov Z; Grekova SP; Bour G; Lehn JM; Giese NA; Nicolau C; Aprahamian M
Int J Cancer; 2014 Jun; 134(11):2572-82. PubMed ID: 24214898
[TBL] [Abstract][Full Text] [Related]
2. Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate.
Limani P; Linecker M; Kachaylo E; Tschuor C; Kron P; Schlegel A; Ungethuem U; Jang JH; Georgiopoulou S; Nicolau C; Lehn JM; Graf R; Humar B; Clavien PA
Clin Cancer Res; 2016 Dec; 22(23):5887-5897. PubMed ID: 27489288
[TBL] [Abstract][Full Text] [Related]
3. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1α suppression and eradication of early hepatoma tumors in rats.
Aprahamian M; Bour G; Akladios CY; Fylaktakidou K; Greferath R; Soler L; Marescaux J; Egly JM; Lehn JM; Nicolau C
Chembiochem; 2011 Mar; 12(5):777-83. PubMed ID: 21370375
[TBL] [Abstract][Full Text] [Related]
4. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
[TBL] [Abstract][Full Text] [Related]
5. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
6. Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes.
Kieda C; Greferath R; Crola da Silva C; Fylaktakidou KC; Lehn JM; Nicolau C
Proc Natl Acad Sci U S A; 2006 Oct; 103(42):15576-81. PubMed ID: 17028170
[TBL] [Abstract][Full Text] [Related]
7. Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors.
Schneider MA; Linecker M; Fritsch R; Muehlematter UJ; Stocker D; Pestalozzi B; Samaras P; Jetter A; Kron P; Petrowsky H; Nicolau C; Lehn JM; Humar B; Graf R; Clavien PA; Limani P
Nat Commun; 2021 Jun; 12(1):3807. PubMed ID: 34155211
[TBL] [Abstract][Full Text] [Related]
8. Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.
Zhao M; Tominaga Y; Ohuchida K; Mizumoto K; Cui L; Kozono S; Fujita H; Maeyama R; Toma H; Tanaka M
Cancer Sci; 2012 Jan; 103(1):58-66. PubMed ID: 21954965
[TBL] [Abstract][Full Text] [Related]
9. Tumour angiogenesis normalized by myo-inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response.
El Hafny-Rahbi B; Brodaczewska K; Collet G; Majewska A; Klimkiewicz K; Delalande A; Grillon C; Kieda C
J Cell Mol Med; 2021 Apr; 25(7):3284-3299. PubMed ID: 33624446
[TBL] [Abstract][Full Text] [Related]
10. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
[TBL] [Abstract][Full Text] [Related]
11. Stable tumor vessel normalization with pO₂ increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment.
Kieda C; El Hafny-Rahbi B; Collet G; Lamerant-Fayel N; Grillon C; Guichard A; Dulak J; Jozkowicz A; Kotlinowski J; Fylaktakidou KC; Vidal A; Auzeloux P; Miot-Noirault E; Beloeil JC; Lehn JM; Nicolau C
J Mol Med (Berl); 2013 Jul; 91(7):883-99. PubMed ID: 23471434
[TBL] [Abstract][Full Text] [Related]
12. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
13. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.
Camp ER; Wang C; Little EC; Watson PM; Pirollo KF; Rait A; Cole DJ; Chang EH; Watson DK
Cancer Gene Ther; 2013 Apr; 20(4):222-8. PubMed ID: 23470564
[TBL] [Abstract][Full Text] [Related]
14. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
[TBL] [Abstract][Full Text] [Related]
15. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Yadav VR; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
Cancer Res; 2010 Nov; 70(21):8695-705. PubMed ID: 20864511
[TBL] [Abstract][Full Text] [Related]
16. Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial.
Limani P; Linecker M; Kron P; Samaras P; Pestalozzi B; Stupp R; Jetter A; Dutkowski P; Müllhaupt B; Schlegel A; Nicolau C; Lehn JM; Petrowsky H; Humar B; Graf R; Clavien PA
BMC Cancer; 2016 Oct; 16(1):812. PubMed ID: 27756258
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of reactive oxygen species by antioxidants suppresses hypoxia-induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells.
Shimojo Y; Akimoto M; Hisanaga T; Tanaka T; Tajima Y; Honma Y; Takenaga K
Clin Exp Metastasis; 2013 Feb; 30(2):143-54. PubMed ID: 22833345
[TBL] [Abstract][Full Text] [Related]
18. Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models.
Tran LB; Cao-Pham TT; Jordan BF; Deschoemaeker S; Heyerick A; Gallez B
J Cell Mol Med; 2019 Mar; 23(3):1908-1916. PubMed ID: 30575283
[TBL] [Abstract][Full Text] [Related]
19. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells.
Kozono S; Ohuchida K; Eguchi D; Ikenaga N; Fujiwara K; Cui L; Mizumoto K; Tanaka M
Cancer Res; 2013 Apr; 73(7):2345-56. PubMed ID: 23348422
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
